fenofibrate All Financial Data in US $ (mln)

Word Search (Top 10 - by date)

Tribute Pharmaceuticals Announces Acquisition of U.S. Rights to Fibricor(R) and Commercial Expansion into U.S. Market
Tribute Pharmaceuticals Canada (May 21, 2015)
Cipher Reports Financial and Operational Results for Q1 2015
Cipher Pharmaceuticals (May 13, 2015)
Amarin Reports First Quarter 2015 Financial Results and Provides Update on Operations
Amarin (May 08, 2015)
New Analysis from Investigational IMPROVE-IT Study Shows VYTORIN® (ezetimibe/simvastatin) Reduced Total (Initial and Recurrent) Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes
Merck & Co (March 16, 2015)
New In Vitro Study Presented at DEUEL Conference on Lipids Suggests Combination Omega-3 Fatty Acid EPA and Atorvastatin May Provide Atheroprotective Benefit
Amarin (March 04, 2015)
Salix Pharmaceuticals Reports 4Q2014 and FY2014 Results
Salix Pharmaceuticals (March 02, 2015)
Cipher Reports Financial Results for Fiscal 2014
Cipher Pharmaceuticals (February 25, 2015)
New Data from IMPROVE-IT Study of VYTORIN® (ezetimibe/simvastatin) and TRA 2ºP TIMI 50 Study of ZONTIVITY® (vorapaxar) to be Presented at American College of Cardiology Scientific Sessions
Merck & Co (February 25, 2015)
Ranbaxy Q3FY 2015 Sales Rs.25,876Mn. YTD Dec’14 Sales Rs.81,778Mn
Ranbaxy Laboratories (January 28, 2015)
VYTORIN® (ezetimibe/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study
Merck & Co (November 17, 2014)

Displaying 10 out of a possible 517 unique stories.
Results Sorted By date
Display All Stories

EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2018) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.

Summary Generic Name Information

Generic Name: fenofibrate
Therapeutic Subcategory:    Anti-hyperlipidaemics

Product Sales Summary

Annual Sales WW - Sales Growth per Year (%)
Rank1 Product Company 2012 2013 2013
Generic Name:2 fenofibrate 1,436 838 -42%
Note: Shaded Cells3

Evaluate - intelligence you can act on

Evaluate delivers market intelligence with standardized, transparent, integrated data that clients rely on.

Choose from a vast array of dynamic reports, customize, edit and download to PDF, Excel or create bespoke reports with expert client support.

Explore Content & Tools


Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.

Explore Evaluate

Register to access more FREE content:

  • 2011 Product Sales analysis
  • Download to Excel
  • Search 2 yrs of company press releases

Register for Free Analysis

Register to access more free insights and analysis from Evaluate.  

Register Now